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Abstract
Objective: Oxidized low-density lipoproteins (ox-LDL) or their components suppress macrophage inflammatory response by
down-regulating cytokine synthesis, nitric oxide synthase and inducible cyclooxygenase (Cox-2). This event is crucial for the
pathophysiological process leading to the formation of atherosclerotic plaque. Our present study focused on the mechanisms through
which oxidized phospholipids inhibit LPS-induced Cox-2 expression in human macrophages. Methods: Macrophages were incubated
with a mixture of oxidized fragmented phospholipids (ox-PAPC), present in modified LDL, and then exposed to LPS. Cox-2 was
evaluated in terms of protein levels, mRNA and activity. Results: Ox-PAPC dose-dependently inhibited Cox-2 protein, mRNA and
activity by preventing NF-kB binding to DNA. This effect was consequent to alterations of the degradation pattern of IkBa. Moreover,
ox-PAPC markedly prevented extracellular signal-regulated kinase (ERK2) activation, leading to Cox-2 expression, whereas activation of
the transcription factor peroxisome proliferator-activated receptors (PPARs) was not influenced. Conclusion: ox-PAPC down-regulates
LPS-induced Cox-2 expression in human macrophages by targeting both NF-kB/IkB and ERK2 pathways. An altered inflammatory
response by macrophages within atheromata may contribute to the progression of atherosclerosis.
 2002 Elsevier Science B.V. All rights reserved.
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1 . Introduction synthesize and release eicosanoids that are potent
modulators of inflammation. The rate-limiting step in their
Macrophages are significant cellular participants synthesis is the enzyme cyclooxygenase (Cox), present in
throughout the development of atherosclerosis, which two isoforms. Cox-1, which is constitutive and detected in
presents features of an inflammatory disease [1]. These most human tissues, and the inducible Cox-2, selectively
cells are engaged to ingest modified lipoproteins, e.g., expressed by a variety of cells exposed to bacterial
ox-LDL, through a variety of scavenger receptors and to lipopolysaccharide (LPS) and cytokines [2]. In macro-
recognize oxidized phospholipids as markers of oxidized phages, Cox-2 induction by LPS is characterized by
moieties, all events that ultimately lead to the generation of ‘redundancy’ both at the extranuclear signaling level and at
the foam cells. the level of transcriptional activation [3]. Mitogen-acti-
Once activated by inflammatory stimuli, macrophages vated protein kinase (MAP-kinase) and protein kinase C
(PKC) are involved in Cox-2 expression by LPS [4,5].
These pathways act, in a coordinate way, with several
*Corresponding author. Tel.: 139-2-5835-8291; fax: 139-2-5835-
8250.
E-mail address: susanna.colli@unimi.it (S. Colli). Time for primary review 27 days.
0008-6363/02/$ – see front matter  2002 Elsevier Science B.V. All rights reserved.
PI I : S0008-6363( 02 )00437-6
S. Eligini et al. / Cardiovascular Research 55 (2002) 406 –415 407
transcription factors, among which the nuclear factor k-B 2 .2. Monocyte culture
(NF-kB) [3,6]. NF-kB activation is controlled by the
family of inhibitors of kB protein (IkB) which retain the Venous blood from healthy donors was obtained in
transcription factor in the cytoplasm. Treatment of macro- accordance with the principles outlined in the Declaration
phages with inflammatory stimuli targets the degradation of Helsinki. Mononuclear cells were separated by Ficoll-
of IkBa and allows NF-kB to translocate into the nucleus Paque density gradient (Pharmacia Fine Chemicals), as
[7]. NF-kB activation is also regulated by members of the described [11]. Monocytes were isolated from lymphocytes
peroxisome proliferator-activated receptors (PPARs) fami- by adherence to six-well plates (2 h at 37 8C, 5% CO ).2
ly, through a mechanism termed ‘transrepression’ [8–10]. Cell preparations were .90% monocytes, as determined
Different isoforms of PPARs have been identified so far; in by nonspecific esterase staining. Macrophages were ob-
particular, PPARg activation has been shown to down- tained by culturing monocytes for 7 days at 37 8C in a 5%
regulate several inflammatory responses of monocytes and CO humid atmosphere in M-199 containing 2 mM2
macrophages, among which is the production of inflamma- glutamine, 0.5% antibiotics and 10% human heat-inacti-
tory cytokines [8]. vated AB serum. They were identified by the presence of
We have previously shown that ox-LDL and its phos- CD68Ag detected by a specific monoclonal mouse anti-
pholipid component as well, impairs Cox-2 in human human macrophage antibody (Dako). The endotoxin con-
macrophages, an effect mimicked by ox-PAPC, a surrogate tent of all culture materials and reagents was measured
for oxidized phospholipids obtained by autoxidation of with the Limulus assay. Unless otherwise specified, macro-
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine phages were incubated with various agents in serum-free
[11]. Ox-PAPC has been identified as a component of medium containing 0.2% fatty acid-free bovine serum
minimally oxidized LDL and its molecular structure and albumin for 2 h. Medium was then removed and macro-
biological activities have been characterized [12,13]. phages were exposed for further 4 h to fresh medium
In this study we have investigated the mechanisms containing LPS (1 mg/ml). This experimental protocol was
through which ox-PAPC impairs Cox-2 in human macro- adopted in order to avoid a direct interaction between LPS
phages. and ox-PAPC, since the formation of a stable complex
LPS/ox-LDL has been reported [14]. Incubation time and
LPS concentration were selected on the basis of results
2 . Materials and methods obtained in preliminary experiments. Macrophage viability
was assessed by Neutral Red and MTT assay.
2 .1. Reagents
2 .3. Cyclooxygenase activity
Cell culture medium and reagents were from BioWhit-
taker. Lipopolysaccharide (E. coli 0114:B4) was from Macrophages were washed with Hanks’ buffer (pH 7.4)
Difco Labs. Benzamidine hydrochloride, leupeptin containing 1 mg/ml BSA and incubated with the same
hemisulfate, soybean trypsin inhibitor, sodium orthovana- buffer containing 10 mM sodium arachidonate. After 30
date, 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phospho- min, supernatants were harvested and the amount of TxB2
choline (PAPC), bovine serum albumin (fatty acid-free and released in the supernatant was measured by enzyme
low endotoxin), clofibrate, neutral red, 3-(4,5-dimethyl- immunoassay (Cayman Chemicals), as previously de-
thiazol-2-yl)2,5-di-phenyltetrazolium bromide (MTT) and scribed [11].
bisphenol A diglycidyl ether (Der Resin 332, BADGE)
were from Sigma. EDTA and NaF was from Carlo Erba. 2 .4. Cell extract and Western blot analysis
Electrophoresis reagents were from Pharmacia Biotech. Wy
12,1414,643 and 15-deoxy-D -prostaglandin J (15d-PGJ ) Whole cell lysates were prepared in RIPA buffer con-2 2
was from Biomol, 13-oxo-octadecadienoic acid (13-ox- taining 5 mM sodium orthovanadate, 100 mM NaF, 5
oODE) was from Cayman Chemicals and TRIzol Reagent mg/ml leupeptin, 5 mg/ml aprotinin, 2 mM pefabloc.
from Life Technologies. BRL-49653 was a kind gift by Dr. Protein content was determined by the micro-bicinchoninic
S. Trowbridge (SmithKline Beecham Pharmaceuticals). acid assay [15]. For cytosol extract preparation, macro-
Ox-PAPC was prepared according to Watson by transfer- phages were washed twice in ice-cold TBS, harvested in
ring 1 mg PAPC in 100 ml of chloroform to a clean 100 ml buffer A (10 mM Hepes, pH 7.9, 1.5 mM MgCl ,2
16325-mm glass test tube and evaporating the solvent 10 mM KCl, 0.5 mM DTT) and incubated for 15 min on
under nitrogen stream [12]. The lipid residue was allowed ice. Triton X-100 (0.4%) was added. Cytosols were
to oxidize on exposure to air for 48 h. Caution was taken separated from nuclei by centrifugation at 15 0003g for 1
to avoid LPS contamination that was checked by the min at 4 8C. SDS–PAGE was performed as previously
Limulus amebocyte lysate assay test (BioWhittaker). described [11]. Membranes were subsequently incubated
Aliquots of ox-PAPC were stored at 280 8C under nitrogen for 1 h at room temperature with monoclonal antibodies
and used within 1 week. raised against Cox-2, mAb 29 (1/10 000) or Cox-1, mAb
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10 and 11 (5 mg/ml), kindly donated by A. Habib, U 348, 2 .6. Nuclear extracts and electrophoretic mobility shift
INSERM, Paris. Antibodies directed against the C-terminal assay
PPARg peptide (monoclonal, 1 /500), against IkBa (poly-
clonal, 1 /500), and against haem-oxygenase-1 (polyclonal, Nuclear extracts were prepared from cell suspensions
1/2000) were from Santa Cruz Biotechnology. MAP- using a protocol according to Dignam et al. [18], slightly
kinase immunoblotting was performed using antibodies modified [19]. The nuclear pellet was washed with 1 ml
(1 /1000) against phosphospecific p44–p42 MAP-kinase buffer B (20 mM Hepes, pH 7.9, 400 mM NaCl, 25%
(Thr202/Tyr204, monoclonal, New England Biolabs, Cel- glycerol, 1.5 mM MgCl , 0.2 mM EDTA, 0.5 mM PMSF,2
180 / 182bio) and p38-kinase (pTpY , polyclonal, Biosource and 0.5 mM DTT). Samples were vortexed for 30 min at
International), as previously described [16]. Blots were 4 8C. Debris was removed by centrifugation at 13 0003g
incubated with donkey anti-mouse or anti-rabbit IgG for 10 min. After supernatant collection, the protein
conjugated with peroxidase (Jackson ImmunoResearch) at content was determined and electrophoretic mobility shift
1 /5000 for 1 h at room temperature. Monoclonal antibody assays were performed as follows: the synthetic single-
directed against b-actin (Sigma) was used as internal stranded oligonucleotides (Eurogentec, Herstal, Belgium)
standard for control of protein load. ECL substrates containing the proximal and distal NF-kB sites were
(Amersham) were used to reveal positive bands that were annealed with the complementary primers and radiolabeled
32
visualized after exposure to HyperfilmTM ECL (Amer- with [ P]dCTP (Amersham). The consensus sequences for
sham). NF-kB are underlined: distal NF-kB site (upstream, within
2455 to 428 from the transcriptional start site) 59-
2 .5. RNA extraction and reverse transcriptase- GGCGGGAGAGGGGATTCCCTGCGCCCCC-39; proxi-
]]]]]
polymerase chain reaction (RT-PCR) mal NF-kB site (downstream, within 2232 to 205 from the
transcriptional start site) 59-CAGGAG-
Total cellular RNA was extracted from macrophages AGTGGGGACTACCCCCTCTGCT-39 [20]. Nuclear ex-
]]]]]
with TRIzol Reagent. Cox-2 mRNA levels were detected tracts (4 mg) were incubated for 20 min at room tempera-
32
using a coupled reverse transcription-polymerase chain ture with 100 000 cpm of P-labeled double-strand oligo-
reaction (RT-PCR) performed using a GeneAmp RNA nucleotides. Reactions were performed in binding buffer
PCR kit (Perkin-Elmer) according to the manufacturer’s (18 ml) containing 60 mM KCl, 20 mM Hepes, 1 mM
instructions. To identify Cox-2 mRNA, exact primers were EDTA, 15 mM DTT, 12% glycerol and 4 mg poly(dI /dC)
synthesized by an analytical RT-PCR procedure developed (Amersham). Protein–DNA complexes were separated
for human cyclooxygenase. Cox-2 primers were 59- from free DNA probe by electrophoresis through 5%
TTCAAATGAGATTGTGGAAAATTGCT-39 (a 27-mer nondenaturating acrylamide gels in 0.53TBE (45 mM Tris
sense, oligonucleotide at position 573) and 59-AGAT- base, 45 mM boric acid, 1 mM EDTA). Gels were dried
CATCTCTGCCTGAGTATCTT-39 (a 24-mer antisense and subjected to autoradiography. NF-kB specific bands
oligonucleotide at position 878), giving rise to a 305-bp were confirmed by competition with a 100-fold molar
PCR product [17]. Primers were also synthesized to excess of an unlabeled NF-kB probe.
amplify the cDNA encoding GAPDH, a constitutively
expressed gene, as control. GAPDH primers were 59- 2 .7. Transfection assays
CCACCCATGGCAAATTCCATGGCA-39 (a 24-mer
sense oligonucleotide at position 216) and 59- CHO cells grown in F-12 medium were transiently
TCTAGACGGCAGGTCAGGTCCACC-39 (a 24-mer anti- transfected using a calcium phosphate precipitation meth-
sense oligonucleotide at position 809) giving rise to a od, as described by Sambrook et al. [21]. A reporter
593-bp PCR product. RNA concentration was determined construct containing three copies of a consensus PPRE
spectrophotometrically. Total cellular RNA from each cloned upstream of the thymidine kinase-luciferase report-
sample (1 mg) was reverse transcribed at 37 8C for 1 h. er (J -TK-LUC) was used [22]. The control vector pRSV-3
The same amount of the resulting cDNA was used for galactosidase (Promega) was cotransfected as a control for
amplification by specific primer for human Cox-2. PCR transfection efficiency. The cells were plated in six-well
amplification was carried out, in the presence of 0.2 mM plates and transfected when 80–90% confluent, 3 h after a
primers, using a thermal cycler GeneAmp PCR System complete medium replacement. Cells were incubated with
2400 (Perkin-Elmer). The following conditions were used: calcium phosphate-precipitated DNA (1 mg plasmid/well)
30 cycles with denaturation at 94 8C for 1 min; primer for 5 h. After shock (2-min glycerol, 15%, v/v), fresh
annealing at 55 8C for 1 min: extension at 72 8C for 1 min. medium containing stimuli was added and cells were
The amplification of human GAPDH was used as internal harvested 2 h later. Supernatants were removed and
standard. Aliquots (10 ml) of amplified products were luciferase production was measured on cell lysates using a
resolved by electrophoresis through a 2% agarose gel. commercially available kit (Promega). After scraping, cells
Amplified cDNA bands were detected by ethidium bro- were transferred into Eppendorf tubes, vortexed, subjected
mide staining. to freezing and thawing and finally centrifuged at 12 0003
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g for 15 s. Aliquots of supernatants (20 ml) were mixed with ox-PAPC (5 mg/ml) for 4–24 h. In contrast, exposure
with the luciferase substrate reagent and absorbancies were to 1 mg/ml LPS for 4 h induced appreciable expression of
determined by a fluorimeter (Lumat LB 9501, Berthold). Cox-2, recognized as a double band at 70 kDa. Ox-PAPC
b-Galactosidase activity was determined by standard assay incubated for 2 h before LPS diminished the amount of
(Invitrogen). Luciferase data were corrected for b-galacto- Cox-2 in a concentration-dependent manner (Fig. 1A). The
sidase activity and are reported as percentage activity same extent of inhibition was observed when ox-PAPC
compared with control cells. was incubated longer (up to 24 h) before LPS addition (not
shown). In contrast, ox-PAPC added concomitantly with,
2 .8. Statistical analysis or 1 or 2 h after LPS did not affect Cox-2 (Fig. 1B).
Subsequent experiments therefore were performed in
Data are reported as means6S.E.M. Computer-assisted macrophages exposed to ox-PAPC for 2 h prior to LPS.
statistical analyses used the ANOVA program, and prob- Ox-PAPC reduced Cox-2 activity, measured as thrombox-
ability values were calculated using Fisher’s protected ane B (TxB ) released in the supernatant (Fig. 1C). The2 2
least-significant difference test. A value of P,0.05 was maximal concentration of ox-PAPC used throughout the
considered significant. study (10 mg/ml) has been reported to be present in 100
mg/ml ox-LDL [23].
Ox-PAPC (10 mg/ml) did not influence macrophage
3 . Results viability as assessed by Neutral Red (.90% macrophages
were viable). A minor decrease of the cell number was
3 .1. Ox-PAPC inhibits LPS-induced Cox-2 in human observed by MTT test, which suggests a very limited, if
macrophages any, toxicity.
Under these experimental conditions, the expression of
Macrophages differentiated from monocytes (7-day cul- Cox-1 was not influenced (not shown).
ture) did not express Cox-2, nor did they after incubation Cox-2 is characterized by the presence of a haem group.
Fig. 1. Ox-PAPC concentration-dependently inhibits Cox-2 and thromboxane B (TxB ) formation in LPS-stimulated macrophages. (A) Macrophages were2 2
incubated with medium or with ox-PAPC (1–10 mg/ml) for 2 h. LPS (1 mg/ml) was added and incubated for further 4 h. (B) ox-PAPC (5 mg/ml) was
added to macrophage culture 2 h before, simultaneously with or after (1 or 2 h) LPS. Cox-2 and b-actin were determined in macrophage lysates by Western
blot analysis. (C) Cox-2 activity was measured in macrophage supernatants as TxB formation, by EIA. Results are the means6S.E.M. of three2
independent experiments. *P,0.01 versus basal; [P,0.01 versus LPS.
410 S. Eligini et al. / Cardiovascular Research 55 (2002) 406 –415
The possibility that ox-PAPC impairs Cox-2 levels through degradation (Fig. 3B). The effect was concentration-depen-
an increased expression of the haem-degrading enzyme dent (Fig. 3C).
haem oxygenase-1 (HO-1) was therefore tested. Ox-PAPC
was ineffective to induce HO-1, ruling out a role of this 3 .3. Ox-PAPC inhibits LPS-induced p38 and ERK2
enzyme in the observed decrease of Cox-2 levels (not activation in human macrophages
shown).
Reduction of Cox-2 protein levels was consequent to NF-kB activation in LPS-stimulated macrophages is
attenuation of Cox-2 mRNA levels, as assessed by RT- under the control of MAP-kinase [3]. To define the role of
PCR. In contrast unoxidized PAPC did not affect Cox-2 MAP-kinase cascade in Cox-2 induction by LPS, human
mRNA (Fig. 2). macrophages were preincubated for 30 min with 25 mM
PD098059, a specific inhibitor of ERK1/2 activity and
3 .2. Ox-PAPC inhibits LPS-induced NF-kB activation in with 10 mM SB203580, which is specific for p38 kinase.
human macrophages by altering the degradation of IkBa Macrophages were then exposed to LPS for further 4 h.
LPS-induced Cox-2 was prevented by PD098059 but not
Ox-LDL are known to influence the expression of by SB203580 (not shown), which suggests a pivotal role of
several LPS-induced inflammatory genes by interfering ERK1/2 in LPS-induced Cox-2 expression in human
with NF-kB activation [24–26]. Nuclear extracts of macro- macrophages.
phages exposed to LPS for 45 min formed a DNA–protein The hypothesis that ox-PAPC interferes with MAP-
complex with the distal NF-kB sequence which was kinase pathway was tested by a Western blot technique
prevented if a 100-fold excess of unlabeled NF-kB probe using antibodies specific for the phosphorylated forms of
has been added (Fig. 3A). No DNA–protein complex was p38 and ERK1/2. Compared to unstimulated macrophages,
observed when the proximal NF-kB sequence was used as bands corresponding to the phosphorylated isoform of p38
a probe (data not shown). This is in agreement with results kinase and ERK2, respectively, were evident in macro-
published by Barrios-Rodiles et al. in the same cell type phages exposed to LPS (Fig. 4). The band appeared within
[20]. 10–20 min, with a peak at 30–40 min and values still
Ox-PAPC concentration-dependently diminished the above the basal level by 60 min (Fig. 4A). Ox-PAPC (5
amount of the DNA–protein complex (Fig. 3A), which mg/ml) almost completely reduced p38 and ERK2 phos-
suggests that Cox-2 expression is impaired by the preven- phorylation (Fig. 4A). The effect of ox-PAPC on both
tion of NF-kB translocation. kinases was concentration-dependent (Fig. 4B)
To further explore the mechanisms involved in the effect
of ox-PAPC on NF-kB activation, the pattern of IkBa 3 .4. Effect of PPAR activators on LPS-induced Cox-2
degradation was evaluated. LPS-treatment of macrophages
resulted in a loss of immunoreactive IkBa protein, de- Ox-PAPC represents a natural ligand of PPARa in
tected at 30 min from LPS addition (Fig. 3B). Macro- human endothelial cells [27,28]. The presence of PPARa
phages, pretreated with ox-PAPC exhibited a reduced IkBa has been detected in human monocytes [29], whereas in
monocytes differentiated into macrophages, the PPARg
isoform predominates [29]. The presence of PPARg was
detected in differentiated macrophages obtained in our
culture condition (not shown). To investigate whether
PPAR activation is involved in the NF-kB-mediated inhibi-
tion of Cox-2, we exposed macrophages for 2 h to a series
of PPAR ligands. The synthetic PPARa ligand Wy 14,643
(100 mM) and clofibrate (500 mM), did not affect Cox-2
(Fig. 5A). Similarly, BRL-49653, a synthetic high affinity
PPARg ligand (Fig. 5B) did not affect Cox-2, even when
incubated with macrophages for much longer time (up to
24 h) before LPS addition (not shown). The natural PPARg
ligand 13-oxoODE did inhibit Cox-2 expression (Fig. 5B),
but only at 50 mg/ml, a concentration twice as high as that
reported to activate PPARg [30]. Another natural PPARg
Fig. 2. Ox-PAPC decreases Cox-2 mRNA, PAPC does not. Macrophages ligand, 15d-PGJ [31,32], concentration-dependently de-2
were incubated with medium (lanes 1 and 2) or with PAPC (5 mg/ml), creased Cox-2 protein (Fig. 5C).
either oxidized (lane 4) or unoxidized (lane 3) for 2 h. LPS (1 mg/ml) Transient transfection experiments were carried out in
was then added for 1 h. Total RNA was extracted and Cox-2 and GAPDH CHO cells, which express PPARg [33], using a reporter
mRNA levels were estimated by RT-PCR. The sequences of the primer
plasmid containing three copies of a consensus PPREsets and oligonucleotide probes for Cox-2 and GAPDH are given in
Section 2. Results are representative of three independent experiments. upstream of a luciferase reporter gene (J -TK-LUC). Ox-3
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Fig. 3. Ox-PAPC inhibits LPS-induced NF-kB translocation and reduces IkBa degradation in human macrophages. (A) EMSAs for the distal NF-kB probe
were performed on nuclear extracts of macrophages treated with medium alone (lanes 1 and 2) or with medium supplemented with ox-PAPC (1–5 mg/ml)
(lanes 3–5). Macrophages were then exposed to LPS (1 mg/ml) for 45 min. Specificity of the binding was determined on cell extracts by competition,
using a 100-fold excess of unlabeled distal probe (lane 6). Results are representative of three independent experiments. (B) Macrophages pretreated with
ox-PAPC (5 mg/ml) or medium alone were stimulated with LPS for the indicated times. (C) Ox-PAPC concentration-dependently reduces IkBa
degradation. Analysis of IkBa protein content was performed by Western blot on cytosolic extracts, as described in Section 2. Results are representative of
three independent experiments.
PAPC (5 mg/ml, 2-h incubation) did not affect luciferase 4 . Discussion
activity. In contrast, BRL-49653 (10 mM), Wy 14,643 (100
mM) and 15d-PGJ (10 mM), increased PPRE-luciferase Oxidized phospholipids are important markers for recog-2
activity within 2 h (Fig. 6). These data together make it nition of oxidized moieties by macrophages and therefore
unlikely an effect of ox-PAPC on Cox-2 via PPAR represent potential modulators of the atherogenic process.
activation. Moreover, BADGE, an antagonist of PPARg Within this context, ox-PAPC provides a useful tool to
ligands that prevents the transcriptional action of the investigate mechanisms of inflammation related to
receptor [34] did not affect the inhibition of Cox-2 exerted atherogenesis [35,36]. This mixture of fragmented phos-
by ox-PAPC (data not shown). pholipid can be indeed formed ‘in vitro’ by free-radical
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Fig. 4. Ox-PAPC inhibits LPS-induced MAP-kinase activation in human macrophages. (A) Macrophages, preincubated for 2 h with ox-PAPC (5 mg/ml) or
with medium alone were exposed to LPS (1 mg/ml) for indicated times. (B) Ox-PAPC concentration-dependently inhibits MAP-kinase activation.
MAP-kinase immunoblotting was performed using antibodies against phosphospecific p44–p42 (ERK1/2) and p38-kinase, as described in Section 2.
Results are representative of three independent experiments.
treatment of unsaturated phospholipids and data from ‘in degradation. This mechanism is identical to that described
vivo’ studies indicate that levels of oxidized phospholipids for ox-LDL in mononuclear phagocytes and considered as
are increased in fatty streak lesions from cholesterol fed responsible for the inhibition of several inducible genes
rabbits [13]. In addition, increased plasma levels of necessary for the inflammatory response [25].
fragmented phosphatidylcholine in response to various Besides the inhibition of NF-kB binding to DNA, we
forms of oxidative stress have been reported in human and show, for the first time, that ox-PAPC acts also by
rat [37]. preventing LPS-induced activation of both p38 and ERK2.
In this study we show that ox-PAPC quickly inhibits This finding suggests that oxidized phospholipids may act
Cox-2 expression induced by LPS in macrophages by as potential modulators of a signal transduction pathway
interfering with NF-kB/IkBa and MAP-kinase pathways. leading to the expression of a variety of genes associated
The capacity of ox-PAPC to target multiple steps involved with the inflammatory response. Interestingly, from our
in Cox-2 expression that act in a coordinate way to data obtained with specific inhibitors of MAP-kinases, it
transduce signals from LPS to nucleus might explain the emerges that only ERK1/2 is involved in Cox-2 expres-
marked inhibitory effect observed. Inhibition of NF-kB sion induced by LPS. This finding is in accordance with a
activation by ox-PAPC is consequent to alteration of IkB recent report which addresses a role of ERK1/2 in Cox-2
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Fig. 6. Effect of ox-PAPC and PPAR agonists on PPRE activation in
transiently transfected CHO cells. Transfections were performed in 80–
90% confluent cells using a reporter plasmid containing three copies of a
consensus PPRE upstream of a luciferase gene. The control vector
pRSV-galactosidase was cotransfected as a control for transfection
efficiency. Cells were treated for 2 h with ox-PAPC (5 mg/ml), BRL-
49653 (10 mM), WY 14,643 (100 mM) and 15d-PGJ (10 mM).2
Luciferase data were corrected for b-galactosidase activity and are
reported as percentage activity compared with control cells. Values are the
means6S.E.M. of five individual experiments.
[38], may explain the lack of effect of SB203580 on
Cox-2, observed in our condition. Whether activation of
ERK2 results in IkB phosphorylation which, in turn,
inhibits NF-kB translocation is an attractive issue that
deserves further investigation.
A role of ox-PAPC as a regulator of gene transcription
has recently been proposed [27,28]. In particular, ox-PAPC
exerts, via a PPARa-mediated mechanism, a proinflammat-
ory effect in that it stimulates the synthesis of specific
monocyte adhesion molecules and monocyte activators by
endothelial cells [28]. Interestingly, the same authors
described an anti-inflammatory effect of PPARa-activators
in LPS-stimulated endothelial cells [39]. These apparently
discrepant results allowed the conclusion that PPAR lig-
Fig. 5. Effect of PPAR ligands on LPS-induced expression of Cox-2 in
ands behave differently depending upon the presence of anhuman macrophages. Macrophages were incubated for 2 h in medium inflammatory stimulus in the experimental system.alone or in medium containing the PPARa ligands WY 14,643 (100 mM)
Our data rule out a role of PPAR activation in Cox-2or clofibrate (500 mM) (A) and the PPARg ligands BRL 49653 (10 mM),
13 oxo-ODE (50 mg/ml) (B) or 15d-PGJ (5–30 mM) (C). LPS (1 inhibition by ox-PAPC. Cox-2 levels are negatively affect-2
mg/ml) was then added, where indicated, for an additional 4 h. Cox-2 and ed by the natural PPARg ligands 13-oxoHODE and 15d-
b-actin proteins were determined in macrophage lysates as described in PGJ . 13-HODE, however, has been reported to act also as2Fig. 1. This figure is representative of three independent experiments.
selective inhibitor of classical protein kinase C isoenzymes
[40] and this signaling pathway is recognized as being
critically involved in LPS-mediated induction of Cox-2
transcription through the NF-kB site [3]. The observation [5]. 15d-PGJ has been recently shown to inhibit Cox-22
that p38 and NF-kB activation are under the control of expression by PPARg-independent mechanisms, by affect-
separate pathways, at least in LPS-activated macrophages ing multiple steps in NF-kB signaling pathways [41–43].
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contribute to the resolution of the inflammatory response. density lipoprotein that induce monocyte /endothelial interactions
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1997;272:13597–13607.activated is crucial for the resolution of inflammation, and
[13] Leitinger N, Watson AD, Hama SH, Ivandic B, Qiao J-H, Huber J,
consequently an impaired prostaglandin formation in foam Faull KF, Grass DS, Navab M, Fogelman AM, de Beer FC, Lusis
cells, coupled with a reduction of cytokine synthesis AJ, Berliner JA. Role of group II secretory phospholipase A2 in
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